Epigral bets ₹600 cr on epoxy, lifts growth target to 20%
Q1 revenue rose 15% to ₹709 cr with 25% margin as board clears forward integration into epoxy resins. Management targets ₹5,000 cr top line at optimal capacity.
— 4 earlier stories on Epigral Ltd. →What's new
- Board approves ₹600 cr capex for a 125,000 tpa epoxy and multipurpose plant.
- Internal growth target raised to 20% or higher, targeting 15-20% CAGR over 3-5 years.
- Management projects peak revenue of ₹5,000 cr from optimal capacity, with ₹1,300-1,500 cr from new projects.
Why this matters
Epigral is moving downstream from its epichlorohydrin base — a strategic pivot that could expand its revenue base significantly. At 12% of market cap, the capex is substantial, but 60% debt funding increases financial risk. Margin trajectory depends on demand recovery.
What we're watching
- Execution timeline for the epoxy plant and any further capacity details.
- Demand recovery and logistics improvement after near-term softness flagged.
- Debt levels and impact on the current low D/E of 0.25.
The full read
Epigral's Q1 was solid: ₹709 crore revenue, up 15%, with EBITDA of ₹179 crore and a 25% margin. But the real news is the board's ₹600 crore bet on epoxy resins: a 125,000-tonne plant that forward-integrates from the company's epichlorohydrin base. It is a strategic pivot that management hopes will drive top line to ₹5,000 crore at full capacity. The internal growth target was lifted to 20% or higher, with a 15-20% CAGR over three to five years. The capex will be 60% debt-funded, adding debt to a balance sheet that currently carries a debt-equity of just 0.25. Near-term, demand softness and logistics snags remain. But for a company with ₹4,772 crore market cap, the ₹600 crore investment is a clear signal: management is betting big on downstream chemicals.
Questions answered
- How will Epigral fund its ₹600 cr capex?
- The company plans to use 60% debt and 40% internal accruals, with ₹400 cr capex each in FY27 and FY28.
- What is the capacity of the new epoxy plant?
- The plant will have 125,000 tonnes per annum capacity, combining epoxy resin and multipurpose production.
- What revenue does Epigral expect from these new projects?
- Downstream chlorotoluene derivatives alone could generate peak revenue of ₹1,300-1,500 crore, and total company top line around ₹5,000 crore at optimum capacity.
- What are the near-term challenges flagged by management?
- Management cited near-term demand softness and logistics disruption as headwinds, though existing expansions remain on schedule.
- How does the new growth target compare to current performance?
- Q1 FY27 revenue grew 15% YoY to ₹709 cr, and the internal target is now 20%+ (or 15-20% CAGR over 3-5 years), implying accelerated growth.
Epigral Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on EPIGRAL →- 27 Jul 2026 · 6:09 PM IST Epigral bets ₹600 cr on epoxy, lifts growth target to 20%
- 1d ago Epigral enters epoxy resins with two Dahej plants, capex undisclosed
- 1d ago Epigral bets ₹600 cr on epoxy resins in strategic pivot
- 1d ago Epigral Q1: Revenue up 16%, adjusted PAT jumps 24%
- 1d ago Epigral logs 16% revenue growth in Q1; PAT falls on one-time credit base effect